Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Exclusion Criteria

• •Has a diagnosis of immunodeficiency or is receiving immunosuppressive therapy within 7 days before the first dose of study intervention
• •Has a known additional malignancy that is progressing or requires active treatment within the past 2 years
• •Has known central nervous system (CNS) metastases and/or carcinomatous meningitis
• •Has ocular or mucosal melanoma
• •Has known hypersensitivity including previous clinically significant hypersensitivity reaction to treatment with another monoclonal antibody (mAb)
• •Has an active autoimmune disease that has required systemic treatment in the past 2 years
• •Has an active infection requiring systemic therapy
• •Has known history of human immunodeficiency virus (HIV)
• •Has known history of hepatitis B
• •Has a history of (noninfectious) pneumonitis
• •Has a history of active tuberculosis (TB)
• •Has received prior systemic anticancer therapy within 4 weeks prior to randomization
• •Has received prior radiotherapy within 2 weeks of first dose of study intervention
• •Has had major surgery \<3 weeks prior to first dose of study intervention
• •Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
• •Has participated in a study of an investigational agent within 4 weeks prior to the first dose of study intervention
• •Has had an allogeneic tissue/solid organ transplant
• •Has only mucosal lesions
• •Is not naïve to Talimogene laherparepvec (TVEC) and other oncolytic viruses